Report Description Table of Contents ERCP Market Overview: Expanding Therapeutic Applications, Advanced Endoscopy Platforms, and Recurring Device Demand – (Updated On: 18th-Sep-2026) The Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market was valued at USD 2.25 billion in 2025 and is projected to reach USD 3.92 billion by 2032, expanding at a CAGR of 8.35% during 2026–2032, according to Strategic Market Research. Endoscopic retrograde cholangiopancreatography (ERCP) is an advanced minimally invasive endoscopic procedure that combines a side-viewing duodenoscope with fluoroscopic imaging to access and treat diseases of the bile ducts and pancreatic ducts. The ERCP procedure base remains substantial, with more than 1 million procedures performed annually worldwide and over 600,000 procedures conducted each year in the United States. Major clinical applications include common bile duct stone removal, malignant biliary obstruction management, benign biliary strictures, pancreatic duct disorders, bile leaks, and tissue sampling for cancer diagnosis. Choledocholithiasis (common bile duct stones) remains the largest application segment. Gallstone disease affects approximately 10%–15% of the U.S. population, representing nearly 25 million individuals, and approximately 1 million Americans are diagnosed with gallstones annually. ERCP also plays a critical role in managing malignant biliary obstruction caused by pancreatic cancer, cholangiocarcinoma, and other hepatobiliary malignancies, approximately 42,340 new liver and intrahepatic bile-duct cancer cases are expected in the United States in 2026. Patients with malignant obstruction frequently require biliary drainage and repeated stent replacement, supporting recurring demand for plastic and metal stent systems. Companies are advancing ERCP through next-generation technologies, with Boston Scientific and Olympus offering digital single-operator cholangioscopy platforms such as SpyGlass DS II and high-resolution imaging systems for direct visualization, targeted biopsies, and stone therapy. Cook Medical provides advanced tissue acquisition devices, guidewires, and biliary intervention tools. Overall, the ERCP market is evolving from a procedure-based endoscopy segment into a broader therapeutic gastrointestinal intervention ecosystem. Long-term growth will be supported by increasing biliary and pancreatic disease burden, recurring accessory consumption, infection-control-driven device innovation, expansion of advanced endoscopy centers, and the development of safer, more efficient, and increasingly technology-enabled therapeutic platforms. Key Takeaways—Therapeutic Accessories, Biliary Interventions, and Safer Technologies Define Market Growth By Product Type Endotherapy Devices account for a 54% share, equivalent to USD 1.215 billion in 2025 revenue, and are projected to expand at a CAGR of 8.80% during 2026–2032. Endoscopes and Duodenoscopes represent a 25% share, generating USD 562.5 million in 2025 revenue, and are projected to grow at a CAGR of 7.70% during 2026–2032. Visualization Systems hold a 14% share, corresponding to USD 315.0 million in 2025 revenue, and are expected to record a CAGR of 8.20% during 2026–2032. Energy Devices contribute a 7% share, equivalent to USD 157.5 million in 2025 revenue, and are projected to expand at a CAGR of 7.80% during 2026–2032. By Procedure Type Biliary Procedures account for a 79% share, equivalent to USD 1.778 billion in 2025 revenue, and are projected to expand at a CAGR of 8.20% during 2026–2032. Pancreatic Procedures represent a 21% share, corresponding to USD 472.5 million in 2025 revenue, and are expected to grow at a CAGR of 8.90% during 2026–2032. By Technology Reusable Devices hold a 63% share, representing USD 1.418 billion in 2025 revenue, and are projected to expand at a CAGR of 6.80% during 2026–2032. Hybrid and Disposable Components account for a 37% share, equivalent to USD 832.5 million in 2025 revenue, and are expected to record a CAGR of 11.00% during 2026–2032. By End User Hospitals account for an 82% share, equivalent to USD 1.845 billion in 2025 revenue, and are projected to expand at a CAGR of 8.10% during 2026–2032. Ambulatory Surgery Centers and Specialty Clinics represent an 18% share, corresponding to USD 405.0 million in 2025 revenue, and are expected to grow at a CAGR of 9.50% during 2026–2032. By Geography North America holds a 42% share, representing USD 945.0 million in 2025 revenue, and is projected to expand at a CAGR of 7.70% during 2026–2032. Europe accounts for a 28% share, equivalent to USD 630.0 million in 2025 revenue, and is expected to grow at a CAGR of 7.80% during 2026–2032. Asia-Pacific represents a 22% share, corresponding to USD 495.0 million in 2025 revenue, and is projected to record a CAGR of 10.60% during 2026–2032. Latin America contributes a 5% share, equivalent to USD 112.5 million in 2025 revenue, and is expected to expand at a CAGR of 9.10% during 2026–2032. Middle East & Africa account for a 3% share, representing USD 67.5 million in 2025 revenue, and are projected to grow at a CAGR of 8.70% during 2026–2032. Segment Leadership and Growth Hotspots—Recurring Accessories Lead While Disposable Technology Accelerates By Product Type Leading Subsegment: Endotherapy Devices Leading and Fastest-Growing Subsegment: Endotherapy Devices Endotherapy devices are the largest and fastest-growing product segment, accounting for approximately 54% of the market and generating USD 1.215 billion in revenue in 2025, with a projected CAGR of 8.80% through 2032. Their growth is driven by their ability to transform ERCP from diagnosis into minimally invasive treatment. These devices enable precise ductal access, sphincterotomy, stone extraction using balloons and baskets, and stricture management through dilation and plastic or self-expanding metal stents, improving drainage and treatment outcomes. By Procedure Type Leading Subsegment: Biliary Procedures Biliary procedures account for a 79% share and USD 1.778 billion in 2025 revenue, expanding at a projected 8.20% CAGR through 2032. Their leadership reflects the frequent use of ERCP for common bile duct stone extraction, biliary sphincterotomy, stricture dilation, infected-duct drainage, and stent placement. Biliary procedures generate demand across guidewires, sphincterotomes, extraction balloons, baskets, dilation devices, and plastic or metal stents. Fastest-Growing Subsegment: Pancreatic Procedures Pancreatic procedures represent a 21% share and USD 472.5 million in 2025 revenue and are projected to grow fastest at an 8.90% CAGR during 2026–2032. Growth is supported by pancreatic duct stenting, stone removal, sphincterotomy, stricture dilation, and the treatment of ductal leaks associated with chronic pancreatitis, trauma, or surgery. These procedures are generally more complex and may require multiple guidewires, stents, dilation products, and repeat interventions. By Technology Leading Subsegment: Reusable Devices Reusable devices hold a 63% share, equivalent to USD 1.418 billion in 2025 revenue, and are projected to grow at a 6.80% CAGR through 2032. Hospitals with established ERCP programs continue to rely on reusable duodenoscopes and imaging platforms because their high procedure volumes distribute acquisition and reprocessing costs across numerous cases. Existing equipment bases and trained clinical teams further support continued utilization. Fastest-Growing Subsegment: Hybrid and Disposable Components Hybrid and disposable components account for a 37% share and USD 832.5 million in 2025 revenue and are forecast to expand at an 11.00% CAGR during 2026–2032. This regulatory direction is accelerating demand for disposable endcaps, single-use accessories, and fully disposable scope configurations. By End User Leading Subsegment: Hospitals Hospitals dominate with an 82% market share and USD 1.845 billion in 2025 revenue, with the segment projected to expand at an 8.10% CAGR through 2032. ERCP commonly requires fluoroscopic imaging, anesthesia support, specialist gastroenterologists, sterilization infrastructure, and immediate inpatient care when complications occur. The NIDDK estimates that complications occur in approximately 5% to 10% of ERCP procedures, reinforcing the concentration of complex and emergency cases within hospitals. Fastest-Growing Subsegment: Ambulatory Surgery Centers and Specialty Clinics Ambulatory surgery centers and specialty clinics represent an 18% share and USD 405.0 million in 2025 revenue and are projected to grow at a 9.50% CAGR during 2026–2032. Expansion is concentrated in scheduled, lower-risk ERCP procedures involving stable patients. Shorter stays and specialized endoscopy workflows support outpatient adoption, although emergency drainage, severe infection, complex obstruction, and high-risk patients generally remain hospital-based. By Geography Leading Subsegment: North America North America holds the leading position with a 42% share and USD 945.0 million in 2025 revenue, expanding at a projected 7.70% CAGR through 2032. The region benefits from established interventional-endoscopy centers, broad access to fluoroscopic systems, specialist training, and substantial recurring consumption of ERCP accessories. The more than 600,000 annual procedures reported in the United States provide a large utilization base for scopes, stents, stone-removal products, catheters, and guidewires. Fastest-Growing Subsegment: Asia-Pacific Asia-Pacific represents a 22% share and USD 495.0 million in 2025 revenue and is projected to record the fastest regional growth at a 10.60% CAGR during 2026–2032. Hospital capacity expansion and rising access to therapeutic endoscopy are increasing regional procedure volumes. A Japanese multicenter study found that the average monthly ERCP volume per participating facility increased from 16.1 procedures in fiscal 2016–2017 to 19.3 in fiscal 2022, while the therapeutic share increased from 87.8% to 92.5%. This shift toward intervention-led ERCP supports faster consumption of stents, extraction devices, guidewires, dilation products, and other endotherapy accessories. Market Drivers—Therapeutic Demand and Infection-Control Priorities Reshape ERCP Adoption Expanding Use of ERCP for Immediate Ductal Treatment ERCP demand is increasing because the procedure can diagnose and treat biliary or pancreatic duct abnormalities during the same intervention. Common bile duct stone extraction, sphincterotomy, stricture dilation, infected-duct drainage, stent placement, postoperative leak management, and tissue sampling require direct endoscopic access that MRCP, ultrasound, and other non-invasive imaging methods cannot provide. Updated ASGE quality guidance reports that more than 600,000 ERCP procedures are performed annually in the United States, demonstrating the procedure’s established utilization base. The movement from diagnostic ERCP toward therapeutic ERCP increases revenue generated per procedure because treatment frequently requires multiple consumable devices. A single intervention may involve a guidewire, catheter, sphincterotome, extraction balloon or basket, dilation device, stent, and tissue-acquisition tool. A Japanese multicenter study found that therapeutic procedures increased from 87.8% of ERCP volume in fiscal 2016–2017 to 92.5% in fiscal 2022, while average monthly procedures per participating facility increased from 16.1 to 19.3. Higher treatment intensity directly expands demand for endotherapy accessories and replacement inventory. Infection-Control Requirements Accelerate Hybrid and Disposable Device Adoption Duodenoscope reprocessing remains difficult because reusable instruments contain complex components that can retain biological material after cleaning. The FDA reported higher-than-expected contamination rates in post-market surveillance and recommended that healthcare facilities transition toward designs containing disposable components. Infection-control requirements are therefore shifting purchasing decisions toward duodenoscopes with disposable endcaps, single-use accessories, and fully disposable configurations. This transition changes ERCP spending from primarily capital-equipment procurement toward a combination of equipment and recurring per-procedure purchases. Reusable platforms will remain important in high-volume hospitals, but disposable components reduce reprocessing complexity and potential cross-patient contamination. As regulatory expectations and hospital infection-prevention policies become stricter, manufacturers offering hybrid scopes, disposable components, and comprehensive single-use accessory portfolios are positioned to capture a greater share of new ERCP expenditure. Market Restraints—Clinical Risk, Specialist Dependence, and Diagnostic Substitution Limit Wider Adoption Procedural Complications and Specialist Shortages Restrict ERCP Availability ERCP carries greater clinical risk than standard gastrointestinal endoscopy because it involves duct cannulation, contrast injection, sphincterotomy, stone extraction, and stent placement. The NIDDK estimates that complications occur in approximately 5% to 10% of procedures. These include pancreatitis, bleeding, infection, perforation, and adverse reactions to sedation. An NHS clinical guide reports post-ERCP pancreatitis in approximately 5% of patients, making careful patient selection and post-procedure monitoring essential. The procedure also depends on experienced interventional endoscopists, fluoroscopy personnel, anesthesia support, and teams capable of managing emergencies. These requirements concentrate ERCP in large hospitals and specialized centers, limiting adoption in smaller hospitals, outpatient clinics, and lower-resource healthcare systems. Training demands and procedure-volume requirements can further delay the establishment of new ERCP programs. Non-Invasive Imaging and Reprocessing Costs Limit Routine Use MRCP, ultrasound, computed tomography, and endoscopic ultrasound increasingly replace ERCP when diagnosis alone is required. These methods can identify stones, tumors, strictures, and ductal abnormalities without instrumenting the bile or pancreatic ducts. Consequently, ERCP is generally reserved for cases in which physicians expect to perform stone extraction, drainage, dilation, stenting, leak repair, or tissue collection. This therapeutic focus limits the procedure’s addressable volume within routine diagnostic pathways. Reusable duodenoscopes also require complex cleaning, high-level disinfection, inspection, maintenance, and trained reprocessing personnel. The FDA has identified persistent contamination concerns after reprocessing, increasing compliance costs and encouraging facilities to adopt disposable components. However, the higher per-procedure expenditure associated with hybrid or fully disposable systems can slow adoption among price-sensitive and lower-volume facilities. Competitive Landscape—Integrated Scope and Endotherapy Portfolios Define Market Leadership Olympus Corporation Olympus is one of the leading ERCP companies because it combines reusable duodenoscopes, endoscopic imaging systems, guidewires, sphincterotomes, extraction devices, dilation products, cannulas, and biliary stents within an integrated portfolio. This breadth allows hospitals to obtain both capital equipment and recurring endotherapy accessories from the same supplier, strengthening Olympus’s position across high-volume ERCP centers. According to the company’s FY2025 Annual Securities Report, its Endoscopic Solutions business generated JPY 636.14 billion in revenue, an increase of 8.4%, while the broader Therapeutic Solutions business generated JPY 360.66 billion, up 6.9%. Olympus specifically reported higher sales from ERCP product groups and invested JPY 21.6 billion in its Therapeutic Solutions business, including investment intended to expand endotherapy-device production. These figures cover broader endoscopic and therapeutic portfolios and are not ERCP-only revenue. Boston Scientific Corporation Boston Scientific is another leading participant, particularly in therapeutic ERCP accessories and single-use technology. Its portfolio covers biliary access, guidewires, sphincterotomes, extraction balloons and baskets, dilation devices, cytology tools, biliary stents, cholangioscopy, and the EXALT Model D single-use duodenoscope. The company is strongly positioned in complex stone treatment, malignant biliary obstruction, tissue acquisition, and infection-control-focused procedures. Boston Scientific’s 2025 Form 10-K reported USD 2.916 billion in Endoscopy revenue, compared with USD 2.687 billion in 2024, representing 8.6% reported growth and 7.7% organic growth. The filing identified its biliary, imaging-system, and endoluminal-surgery franchises as principal contributors to 2025 growth. The reported figure covers the company’s complete Endoscopy business and is not limited to ERCP products. Other Participating Companies Fujifilm Holdings Corporation: Supplies high-definition endoscopy systems and duodenoscope platforms used for biliary and pancreatic visualization and intervention. Cook Medical: Provides wire-guided access devices, sphincterotomes, extraction balloons, stone baskets, cytology tools, and biliary and pancreatic stents. Medtronic: Participates through gastrointestinal endoscopy and minimally invasive technologies that complement pancreaticobiliary diagnosis and treatment. CONMED Corporation: Supplies electrosurgical generators and endoscopic accessories used during sphincterotomy and other therapeutic procedures. STERIS plc: Supports ERCP programs through duodenoscope reprocessing, infection-prevention systems, procedure accessories, and endoscopy-unit infrastructure. Ambu A/S: Competes in the infection-control segment through single-use duodenoscope technology intended to eliminate reusable-scope reprocessing. PENTAX Medical–HOYA Corporation: Provides endoscopic imaging platforms and duodenoscopes for biliary and pancreatic procedures. Micro-Tech Endoscopy: Offers guidewires, sphincterotomes, extraction devices, dilation balloons, and biliary stents for therapeutic ERCP. Merit Medical Systems: Participates through interventional catheters, guidewires, drainage products, and complementary gastrointestinal stent technologies. Analyst Perspective—Treatment Intensity and Infection Control Define Future ERCP Value The ERCP market is progressing toward a more treatment-focused and safety-conscious model in which clinical value depends on completing complex interventions efficiently while reducing procedural and infection risks. Future commercial gains will increasingly come from disposable and hybrid technologies, advanced stone-management tools, improved biliary and pancreatic stents, and integrated systems that support faster clinical workflows. Companies that combine reliable visualization with broad endotherapy portfolios, infection-control support, physician training, and strong service networks will be best positioned as therapeutic ERCP expands across established and developing healthcare systems. ERCP Market Report Coverage—Forecast Scope, Segmentation, and Growth Framework Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 2.25 Billion Revenue Forecast in 2032 USD 3.92 Billion Overall Growth Rate CAGR of 8.35% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Product Type, By Procedure Type, By Technology, By End User, By Geography By Product Type Endotherapy Devices, Endoscopes and Duodenoscopes, Visualization Systems, Energy Devices By Procedure Type Biliary Procedures, Pancreatic Procedures By Technology Reusable Devices, Hybrid and Disposable Components By End User Hospitals, Ambulatory Surgery Centers and Specialty Clinics By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Expanding therapeutic ERCP applications, recurring endotherapy accessory demand, infection-control requirements, disposable and hybrid device adoption, and advanced endoscopy-center expansion Customization Option Available upon request Frequently Asked Question About This Report Q1. What is the current market size and expected growth through 2032? A1. The market was valued at USD 2.25 billion in 2025 and is projected to reach USD 3.92 billion by 2032, expanding at a CAGR of 8.35% during 2026–2032, according to Strategic Market Research. Q2. Which clinical applications generate the greatest procedural demand? A2. Major applications include common bile duct stone extraction, biliary drainage, sphincterotomy, benign and malignant stricture management, stent placement, pancreatic duct intervention, bile-leak treatment, and tissue sampling. Biliary procedures dominate, accounting for 79% of market revenue in 2025. Q3. Which product category holds the largest market share? A3. Endotherapy devices are the leading product category, accounting for 54% of the market and USD 1.215 billion in 2025 revenue. Demand is supported by recurring use of guidewires, sphincterotomes, extraction balloons, baskets, dilation devices, tissue-acquisition tools, and biliary or pancreatic stents. Q4. Why do biliary procedures account for most market revenue? A4. Biliary procedures generated 79% of the market and USD 1.778 billion in 2025 because ERCP is extensively used for common bile duct stones, biliary obstruction, strictures, cholangitis-related drainage, sphincterotomy, and stent placement. Many procedures require several disposable accessories, creating recurring revenue beyond the endoscope itself. Q5. Which procedure category is expected to grow the fastest? A5. Pancreatic procedures are projected to grow fastest at a CAGR of 8.90% during 2026–2032. Growth is associated with pancreatic duct stenting, stone extraction, stricture dilation, sphincterotomy, and treatment of ductal leaks related to chronic pancreatitis, surgery, or trauma. Q6. How are infection-control requirements changing device adoption? A6. Infection-control concerns associated with reusable duodenoscope reprocessing are accelerating adoption of disposable endcaps, single-use accessories, hybrid designs, and fully disposable duodenoscopes. Hybrid and disposable technologies accounted for 37% and USD 832.5 million in 2025 and are projected to grow at an 11.0% CAGR, substantially faster than reusable devices. Q7. Why do hospitals remain the primary end users? A7. Hospitals accounted for 82% of the market and USD 1.845 billion in 2025 because procedures often require fluoroscopy, anesthesia, trained interventional endoscopists, reprocessing infrastructure, and immediate management of complications. Complex obstruction, cholangitis, difficult stones, and pancreatic interventions particularly favor hospital-based treatment. Q8. Which region currently generates the largest revenue, and which is growing fastest? A8. North America leads with a 42% share and USD 945 million in 2025 revenue, supported by substantial procedure volumes and developed interventional-endoscopy infrastructure. Asia-Pacific is the fastest-growing region, with a projected 10.60% CAGR during 2026–2032, as therapeutic endoscopy capacity expands across major healthcare systems. Q9. What factors are limiting wider procedural adoption? A9. Major limitations include the risk of post-procedure pancreatitis, bleeding, infection, perforation, and sedation-related complications, along with dependence on highly trained specialists and fluoroscopic infrastructure. In addition, MRCP, ultrasound, CT, and endoscopic ultrasound increasingly replace ERCP when only diagnostic information is required, concentrating its use in therapeutic cases. Q10. Which companies have the strongest positions in the competitive landscape? A10. Olympus and Boston Scientific hold strong positions because they combine established endoscopy technologies with broad therapeutic portfolios. Olympus competes through duodenoscopes, imaging systems, and endotherapy devices, while Boston Scientific has substantial strength in biliary accessories, stents, cholangioscopy, and the EXALT Model D single-use duodenoscope. Fujifilm, Cook Medical, PENTAX Medical, Ambu, CONMED, STERIS, Micro-Tech Endoscopy, Medtronic, and Merit Medical also participate across specific parts of the procedural ecosystem. Sources: 1. ERCP Applications, Utilization, and Clinical Trends NIDDK — Endoscopic Retrograde Cholangiopancreatography Supports the ERCP definition, bile- and pancreatic-duct applications, stone removal, stricture treatment, stenting, leak management, alternative diagnostic methods, and the 5%–10% complication rate. ASGE/Gastrointestinal Endoscopy — Updated Quality Indicators for ERCP Supports U.S. procedure utilization, therapeutic ERCP practices, quality measures, cannulation success, stone clearance, adverse-event monitoring, and specialist requirements. Journal of Gastroenterology — Current Status and Trends in ERCP and Post-ERCP Pancreatitis in Japan Supports the increase in average monthly ERCP volume from 16.1 to 19.3 procedures per facility and the rise in therapeutic procedures from 87.8% to 92.5%. NIDDK — Definition and Facts for Gallstones Supports the estimate that gallstones affect 10%–15% of the U.S. population, or nearly 25 million people, with approximately 1 million diagnoses annually. 2. Cancer Burden and Malignant Biliary Obstruction NCI SEER — Liver and Intrahepatic Bile Duct Cancer Statistics Supports the estimate of 42,340 new combined liver and intrahepatic bile-duct cancer cases in 2026. American Cancer Society — Key Statistics for Bile Duct Cancer Provides a more specific U.S. bile-duct cancer burden estimate. American Cancer Society — Key Statistics for Pancreatic Cancer Supports the pancreatic cancer burden underlying malignant biliary-obstruction demand. NIDDK — ERCP Risks and Complications Supports post-ERCP pancreatitis, infection, bleeding, perforation, and anesthesia-related risks. 3. Infection Control and ERCP Technology FDA — Infections Associated with Reprocessed Duodenoscopes Supports duodenoscope contamination concerns, reprocessing challenges, U.S. procedure utilization exceeding 500,000 annually, and the transition toward disposable components and single-use scopes. Boston Scientific — SpyGlass DS Direct Visualization System Supports direct cholangioscopic visualization, targeted biopsy, and complex biliary-stone treatment. Boston Scientific — EXALT Model D Single-Use Duodenoscope Supports the company’s participation in fully disposable ERCP technology. Olympus — Duodenoscope Portfolio Supports Olympus’s high-resolution duodenoscopy and pancreaticobiliary intervention platform. Ambu — aScope Duodeno 2 Supports Ambu’s participation in the single-use duodenoscope category. 4. Company and Financial Sources Olympus — FY2025 Annual Securities Report Supports Endoscopic Solutions revenue of JPY 636.14 billion, Therapeutic Solutions revenue of JPY 360.66 billion, ERCP product-group growth, and investment in endotherapy-device production. Boston Scientific — 2025 Form 10-K Supports 2025 Endoscopy revenue of USD 2.916 billion, compared with USD 2.687 billion in 2024, and growth contributions from the biliary and imaging-system franchises. Table of Contents - Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Procedure Type, Technology, End User, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Procedure Type, Technology, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Procedure Type, Technology, and End User Investment Opportunities in the ERCP Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Endotherapy Devices, Advanced Endoscopes and Duodenoscopes, Visualization Systems, Energy Devices, Biliary Procedures, Pancreatic Procedures, Reusable Devices, Hybrid and Disposable Components, Hospitals, and Ambulatory Surgery Centers and Specialty Clinics Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of ERCP in Therapeutic Biliary and Pancreatic Interventions and Advanced Gastrointestinal Endoscopy Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Infection-Control Compliance Factors Role of Therapeutic ERCP, Advanced Endoscopy Platforms, Biliary Intervention, Pancreatic Intervention, and Endotherapy Accessories in Market Expansion Recurring Device Demand, Reprocessing Requirements, Disposable Components, and Safer Endoscopic Technologies Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Endotherapy Devices Endoscopes and Duodenoscopes Visualization Systems Energy Devices Market Analysis by Procedure Type: Biliary Procedures Pancreatic Procedures Market Analysis by Technology: Reusable Devices Hybrid and Disposable Components Market Analysis by End User: Hospitals Ambulatory Surgery Centers and Specialty Clinics Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Procedure Type, Technology, and End User Country-Level Breakdown: United States Canada Europe Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Procedure Type, Technology, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Procedure Type, Technology, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia Pacific Latin America Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Procedure Type, Technology, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Procedure Type, Technology, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Competitive Intelligence and Benchmarking Leading Key Players: Olympus Corporation Boston Scientific Corporation Fujifilm Holdings Corporation Cook Medical Medtronic CONMED Corporation STERIS plc Ambu A/S PENTAX Medical–HOYA Corporation Micro-Tech Endoscopy Merit Medical Systems KARL STORZ Richard Wolf GmbH Endo-Flex GmbH Medi-Globe GmbH Competitive Landscape and Strategic Insights Benchmarking Based on Endotherapy Portfolio, Endoscopy Platform Capability, Visualization Technology, Device Reusability, Disposable Component Availability, Infection-Control Support, and Regional Presence Supplier Qualification and Compliance Capability Analysis Advanced Endoscopy Platform Positioning Biliary and Pancreatic Intervention Competitiveness Endotherapy Accessories, Hybrid Technology, Disposable Components, and Reprocessing Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product Type, Procedure Type, Technology, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Regulatory Compliance, Infection-Control, and Procurement Risk Analysis Technology Adoption Trends Across Reusable Devices, Hybrid and Disposable Components, Endoscopy Platforms, Visualization Systems, and Endotherapy Devices List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Procedure Type, Technology, and End User (2025 vs. 2032) Global ERCP Ecosystem and Value Chain Analysis